Vestmark Advisory Solutions Inc. Has $4.49 Million Stock Holdings in The Cooper Companies, Inc. $COO

Vestmark Advisory Solutions Inc. trimmed its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 50.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 63,101 shares of the medical device company’s stock after selling 64,147 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Cooper Companies were worth $4,490,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in COO. Bastion Asset Management Inc. bought a new position in shares of Cooper Companies in the second quarter worth about $8,784,000. Twin Capital Management Inc. increased its holdings in shares of Cooper Companies by 4.8% in the second quarter. Twin Capital Management Inc. now owns 8,074 shares of the medical device company’s stock valued at $575,000 after purchasing an additional 372 shares in the last quarter. Resona Asset Management Co. Ltd. increased its holdings in shares of Cooper Companies by 7.9% in the second quarter. Resona Asset Management Co. Ltd. now owns 67,988 shares of the medical device company’s stock valued at $4,838,000 after purchasing an additional 4,976 shares in the last quarter. South Dakota Investment Council bought a new position in Cooper Companies in the 2nd quarter worth approximately $78,000. Finally, State of Michigan Retirement System lifted its holdings in Cooper Companies by 0.4% during the 2nd quarter. State of Michigan Retirement System now owns 54,344 shares of the medical device company’s stock worth $3,867,000 after buying an additional 200 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

COO has been the subject of several research reports. BNP Paribas raised Cooper Companies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 22nd. Piper Sandler decreased their price target on Cooper Companies from $105.00 to $83.00 and set an “overweight” rating on the stock in a report on Thursday, August 28th. JPMorgan Chase & Co. dropped their price objective on Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday, August 28th. Needham & Company LLC restated a “buy” rating and set a $94.00 target price on shares of Cooper Companies in a research report on Thursday, August 28th. Finally, Wells Fargo & Company lowered their price target on shares of Cooper Companies from $93.00 to $72.00 and set an “overweight” rating for the company in a research report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Cooper Companies Trading Up 1.6%

NASDAQ COO opened at $70.10 on Friday. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $106.63. The stock has a 50-day simple moving average of $69.24 and a 200 day simple moving average of $72.64. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $13.94 billion, a PE ratio of 34.53, a P/E/G ratio of 1.83 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.96 EPS. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. Research analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a stock repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Cooper Companies

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of the business’s stock in a transaction on Monday, September 29th. The shares were bought at an average cost of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the acquisition, the director owned 5,777 shares in the company, valued at approximately $395,089.03. This trade represents a 52.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Albert G. White III purchased 10,000 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was purchased at an average cost of $68.39 per share, with a total value of $683,900.00. Following the acquisition, the chief executive officer directly owned 226,151 shares in the company, valued at $15,466,466.89. This trade represents a 4.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 17,975 shares of company stock valued at $1,216,346. Corporate insiders own 1.98% of the company’s stock.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.